Eli Lilly and Company (LLY)
Best Growth Stocks to Buy for January 8th
MU, LLY and SKIL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 8th, 2026.
Eli Lilly's 2026 Resolution: Volume Is The New Price
Eli Lilly and Company remains a Buy, supported by robust incretin-driven growth and strategic expansion in obesity treatments. LLY pivots from scarcity to access economics, prioritizing volume over net price as orforglipron and ZEPBOUND expand reach. Retatrutide and oral pipeline assets, plus Nimbus and Superluminal deals, diversify revenue and mitigate single-asset risk.
Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1 billion, according to people familiar with the matter
The more-than-$1 billion deal could come imminently.
Are You Looking for a Top Momentum Pick? Why Eli Lilly (LLY) is a Great Choice
Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Eli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note
Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -3.6% change compared to its last close.
3 Reasons Why Lilly (LLY) Is a Great Growth Stock
Lilly (LLY) possesses solid growth attributes, which could help it handily outperform the market.
3 Top Ranked Stocks to Buy for 2026 (LLY, WFRD, PGY)
Eli Lilly, Pagaya Technologies Ltd. and Weatherford International stocks all boast numerous bullish tailwinds heading into this new year.
Wall Street Analysts Think Lilly (LLY) Is a Good Investment: Is It?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Why Eli Lilly Is the Unexpected Must-Buy Dividend Powerhouse to Own in 2026
Dividend growth investing builds long-term wealth for retirement by focusing on companies that consistently increase payouts.
Eli Lilly's New Drug Data Sets Up a High-Stakes 2026
Since early August, the world's most valuable pharmaceutical stock, Eli Lilly and Company NYSE: LLY, has put on a stellar performance. After tanking 14% on Aug. 7 due to poor clinical trial results, shares have gained a whopping 71% year-to-date.
Focus: Lilly, Novo lock horns in India's obesity drug race
Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit shelves in March next year.
